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CC BY-NC-ND license (http://creativeBackground/Purpose: This study aims to examine the cost effectiveness of treating major can-
cers compared with other major illnesses in Taiwan.
Methods: We collected data on 395,330 patients with cancer, 125,277 patients with end-
stage renal disease, and 50,481 patients under prolonged mechanical ventilation during
1998e2007. They were followed for 10e13 years to estimate lifetime survival functions
using a semiparametric method. EuroQol five-dimension was used to measure the quality
of life for 6189 cancer patients and 1401 patients with other illnesses. The mean utility
values and healthcare costs reimbursed by the National Health Insurance were multiplied
with the corresponding survival probabilities to estimate quality-adjusted life expec-
tancies and lifetime costs, respectively. Data of 22,344 cancer patients under hospice
care (considered as a comparison group) were used to conduct a cost-effectivenessave no conflicts of interest relevant to this article.
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610 M.-C. Hung et al.analysis. Sensitivity analysis was conducted by assuming patients without treatment sur-
vived for 2 years with a quality of life value of 0.5.
Results: The costs of care for patients under prolonged mechanical ventilation and those with
end-stage renal disease were US$41,780e53,708 per quality-adjusted life year (QALY) and
US$18,222e18,465 per QALY, respectively, which are equivalent to 2.17e2.79 gross domestic
product (GDP) per capita per QALY and 1.18e1.25 GDP per capita per QALY. The costs of care
for the nine different cancers were less than 1 GDP per capita per QALY, with those of lung,
esophagus, and liver cancers being the highest. Sensitivity analysis showed the same conclu-
sion. Lifetime risks of six out of nine cancer sites show an increased trend.
Conclusion: Cancer care in Taiwan seemed cost effective compared with that of other illnesses,
but prevention is necessary to make the National Health Insurance more sustainable.
Copyright ª 2016, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
Cancer is one of the leading causes of death worldwide and
accounted for 8.2 million (22%) deaths in 2012.1 The burden
of cancer is also increasing due to the aging population in
many countries, and thus cancer-related healthcare ex-
penditures are growing rapidly. Taking Taiwan as an
example, the total number of prevalent cancer cases was
463,703 in 2012, and they accounted for 10.2% of the total
expenditures of the National Health Insurance (NHI) sys-
tem.2 There is thus a growing concern about the financial
burden of caring for cancer patients in Taiwan, and there is
a need to make cancer treatment care more efficient.3,4
Cost-effectiveness analysis has been recommended as a
method to assess national healthcare programs in many
countries.5e7 However, the methodology has not been sys-
tematically applied to quantify how many dollars are spent
per quality-adjusted life year (QALY) gained for cancer care
in Taiwan’s NHI system. Currently, there is an urgent need
to improve resource allocation in the NHI, and to make
more efficient and fair decisions regarding cancer preven-
tion and treatment policies.
This study utilized a generalized cost-effectiveness
analysis method8 to estimate the lifetime cost per QALY
for different cancer sites and for selected patients under
hospice care as a comparison group to conduct a quasi-
incremental cost-effectiveness ratio (quasi-ICER). The re-
sults were compared with those estimated from patients
with end-stage renal disease (ESRD) and patients under
prolonged mechanical ventilation (PMV). We hope that the
estimates from this study can help in deriving a more sus-
tainable policy for cancer care in Taiwan.Methods
Study population and datasets
The study commenced after gaining approval of the Institu-
tional Review Board of the National Cheng Kung University
Hospital, Tainan, Taiwan (IRB number: ER-102-034, A-ER-
101-089). Data of 395,330 patients with pathologically veri-
fied cancer registered with the Taiwan Cancer Registry and
125,277 patients with ESRD (ICD-9-CM code: 585) registeredunder “catastrophic illnesses” during 1998e2007 in the NHI
were collected through the National Health Insurance
Research Database and followed until 2007e2010, as sum-
marized in Figure 1. The reimbursement data file obtained
from the NHI of Taiwan was transformed into a research
database by the National Health Research Institutes (in
Chunan, Taiwan).9 Identification numbers of all individuals
in the file were encrypted to protect their privacy. These
files contained detailed demographic data (including birth
date and sex) and information regarding the healthcare
services provided for each patient, including all payments
for clinical care for outpatient visits, hospitalizations, pre-
scription drugs, diagnoses, and intervention procedures.
In this study, nine major cancers were considered: lung
(ICD-9-CM code: 162), esophagus (ICD-9-CM code: 150), liver
(ICD-9-CM code: 155), stomach (ICD-9-CM code: 151), colo-
rectal (ICD-9-CM code: 153-154), oral (ICD-9-CM code: 140-
141), nasopharyngeal (ICD-9-CM code: 147), cervical (ICD-9-
CM code: 180), and breast (ICD-9-CM code: 174) cancers. In
addition, data of a nationwide systematic random sample of
50,481 patients who were older than 17 years and had
received PMV for > 21 days (ICD-9-CM code: 518.85) during
1998e2007 were collected and they were followed up until
the end of 2007.10 In order to apply generalized cost-
effectiveness analysis,8 it is necessary to have a compari-
son group that is not receiving formal medical care over
natural course of the disease. As all cancer treatments
under internationally established guidelines can be waived
from copayment under the current NHI system, it is almost
impossible to recruit cancer patients who are not receiving
any treatment in Taiwan. We thus assigned 22,344 cancer
patients under hospice care in the comparison group to es-
timate survival, as they only received basic palliative care,
and the quality of life (QoL) value for these individuals was
assumed to be 0.4 in the analysis.11
Survival analysis and extrapolation to estimate life
expectancy for different illnesses
All of the above patients were linked to the Taiwan Mor-
tality Registry to obtain their survival functions via the
KaplaneMeier (KeM) estimation method.12 These were
further extrapolated to lifetime based on a semiparametric
method using the age- and sex-matched referents
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tics.13 Details of this method and its mathematical proofs
have been described elsewhere.10,14e17 Briefly, the method
requires an assumption of constant excess hazards.14,15,18
The estimates were obtained using integration of Survival
with Quality of Life (iSQoL) statistical software (http://
www.stat.sinica.edu.tw/isqol/).Measurements of quality of life data via EuroQoL
five-dimension questionnaire for estimation of
quality-adjusted life expectancy
To estimate the utility value of quality of life (QoL) for
these patients at different duration to dates (from the
diagnosis of disease up to the date of interview), cross-Figure 1 Flow diagram of the computation process for cost per
Taiwan Mortality Registry and extrapolated the results to obtain th
illnesses, which were either adjusted with the QoL data measure
monthly cost to obtain the lifetime cost after being adjusted for
calculated by dividing the lifetime cost by QALE (with 3% discoun
Insurance Research Database; QALEZ quality-adjusted life expectsectional data of 7590 patients from 2008 to 2013 were
used. Written informed consent was obtained from patients
with cancer or ESRD, or those under PMV, or from their
family caregivers. All the patients were receiving inpatient
and/or outpatient care from 17 institutions in Taiwan. The
QoL of these patients was assessed using the EuroQoL five-
dimension questionnaire, which is a preference-based,
generic instrument19e21 that provides a utility value ac-
cording to Taiwan’s value system.22 It ranges from 0 to 1
based on the five-dimensional health state classification, in
which 0 represents the worst health status and 1 the per-
fect health status. In general, a cross-sectional, consecu-
tive sample of patients was obtained, and a kernel-type
smoothing method (using a moving average of the nearby
10%) was performed to estimate the mean QoL across
time.17 The QoL value after the end of the follow-up periodQALY. We linked the Taiwan Cancer Registry and NHIRD to the
e lifetime survival functions for patient cohorts with different
d in EQ-5D to obtain the QALE, or multiplied by the average
an annual discount rate of 3%. The cost per QALY was then
t). EQ-5DZ EuroQoL five-dimension; NHIRDZ National Health
ancy; QALYZ quality-adjusted life year; QoLZ quality of life.
Table 1 Generalized cost-effectiveness analysis for cancer care compared with that for patients under PMV and with ESRD.
Patients with treatment Cost-per-QALYa Patients under hospice care Quasi-ICERb
(utilityZ 0.4)Sex No. Age (SD) QALE (SE) Lifetime costc
(3% discount)
No. Age QALE (utilityZ 0.4) Lifetime costc
(3% discount)
Cancer site
Lung Male 46,165 68.0 (11.6) 2.2 (0.0) 16,610 (891) 9491 (501) 3722 69.8 (11.7) 0.1 (0) 3139 (387) 8091 (561)
Female 22,011 64.9 (13.2) 3.4 (0.0) 20,872 (713) 8089 (303) 2754 66.8 (12.6) 0.11 (0.01) 3619 (389) 6958 (355)
Esophagus Male 12,111 67.7 (13.8) 2.8 (0.1) 18,313 (924) 8576 (502) 889 61.9 (13.2) 0.12 (0.01) 3028 (627) 7515 (646)
Female 954 67.7 (13.8) 4.9 (0.2) 17,091 (1808) 4792 (553) 98 72.5 (12.9) 0.12 (0.02) 4465 (1022) 3650 (688)
Liver Male 29,008 59.3 (13.3) 5.4 (0.1) 19,759 (1025) 4866 (262) 1880 62.9 (13.5) 0.09 (0.00) 2786 (563) 4255 (302)
Female 10,739 62.9 (12.9) 5.7 (0.1) 19,725 (1112) 4847 (284) 875 65.3 (12.8) 0.08 (0.01) 2339 (420) 4350 (311)
Stomach Male 23,173 67.6 (13.2) 5.5 (0.3) 17,435 (1473) 4167 (441) 1618 70.4 (12.9) 0.10 (0.00) 2219 (471) 3715 (462)
Female 12,403 64.1 (15.2) 8.0 (0.4) 17,272 (1344) 3078 (265) 995 66.9 (15.1) 0.15 (0.01) 2608 (485) 2672 (277)
Colorectum Male 43,731 65.4 (13.3) 9.9 (0.1) 24,677 (1741) 3428 (247) 2261 67.7 (13.2) 0.15 (0.01) 3108 (424) 3048 (258)
Female 33,165 51.9 (12.0) 11.8 (0.1) 23,733 (1784) 2926 (226) 2097 67.1 (14.5) 0.10 (0.01) 3450 (399) 2528 (235)
Oral Male 25,897 65.4 (13.3) 11.7 (0.2) 27,498 (1979) 3462 (262) 1469 54.7 (12.5) 0.16 (0.01) 4353 (719) 2961 (289)
Female 2854 59.5 (15.5) 13.3 (0.2) 24,147 (1549) 2615 (179) 196 67.2 (15.3) 0.11 (0.01) 3754 (777) 2233 (198)
Nasopharynx Male 10,459 49.8 (13.2) 11.9 (0.3) 29,809 (3105) 3578 (378) 453 54.6 (13.6) 0.26 (0.02) 5783 (840) 2955 (402)
Female 3701 49.2 (13.8) 18.0 (0.4) 30,225 (3066) 2676 (274) 179 56.6 (13.8) 0.52 (0.03) 5398 (782) 2273 (291)
Breast Female 59,412 51.2 (12.1) 21.3 (0.2) 28,180 (1452) 2054 (106) 1718 57.3 (13.5) 0.34 (0.01) 5007 (508) 1720 (111)
Cervix Female 59,547 51.3 (14.6) 25.9 (0.3) 17,645 (1147) 1107 (72) 1140 62.5 (14.5) 0.28 (0.02) 4809 (606) 816 (88)
PMV Male 30,298 71.1 (14.6) 0.8 (0.1) 25,225 (2517) 41,780 d d d d 41,780
Female 20,183 73.2 (14.5) 0.8 (0.1) 32,260 (3292) 53,708 d d d d 53,708
ESRD Male 61,241 60.4 (15.0) 7.5 (0.1) 129,658 (2885) 22,714 (534) d d 0.20 d 18,222
Female 64,036 62.0 (14.6) 7.7 (0.1) 138,487 (3248) 24,180 (605) d d 0.20 d 18,465
ESRDZ end-stage renal disease; ICERZ incremental cost-effectiveness ratio; PMVZ prolonged mechanical ventilation; QALEZ quality-adjusted life expectancy; QALYZ quality-
adjusted life year; SDZ standard deviation; SEZ standard error of mean.
a Cost per QALY; both QALE and lifetime cost were applied (with 3% discount).
b Quasi-ICER, calculated based on the difference in comparison to patients under hospice care, and both QALE and lifetime cost were
applied (with 3% discount).
c Lifetime cost (in US dollars at a 3% discount rate) paid by the National Health Insurance of Taiwan.
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Figure 2 Comparison of cost per QALY (3% discount) for
different types of cancers, patients under PMV, and patients
with ESRD, stratified by gender: (A) males and (B) females.
ESRDZ end-stage renal disease; PMVZ prolonged mechanical
ventilation; QALEZ quality-adjusted life expectancy;
QALYZ quality-adjusted life year.
Cost effectiveness of cancer care in Taiwan 613was assumed to be the same as the average of the last 10%
of measurements through smoothing. The lifetime survival
probabilities of a cancer under study were multiplied (or
adjusted) with the QoL utility values to obtain a quality-
adjusted survival curve. The total area under this curve
was the quality-adjusted life expectancy (QALE),17 as
shown in Figure A1.
Lifetime healthcare expenditures paid by the NHI
for different illnesses
The lifetime healthcare expenditures were estimated by
counting the monthly average dollars reimbursed by the
NHI during 1998e2009 for these patients, from the day of
validated diagnosis or hospice care to the end of life or
till being censored.23 The calculation process was as
follows. The average monthly expenditures, including the
costs of inpatient, outpatient, and emergency care, were
summed for each patient. Each month, the aggregate
expenditure was divided by the number of patients who
were still alive to estimate the monthly average costs to
the NHI. Annual NHI expenditures were first adjusted to
the 2010 monetary value using the Consumer Price Index.
The adjusted annual expenditure was discounted at a
rate of 3% following the recommendation of the US Cost-
Effectiveness Panel.5 The total average monthly expen-
ditures were multiplied by the monthly survival proba-
bilities for each illness over a lifetime. All the estimated
monetary values were summed to obtain the lifetime
healthcare expenditure for each major catastrophic
illness, as shown in Figure A2.
Estimation of cost per QALY for different illness
groups
The ICER was estimated using the following formula:
(average total lifetime cost of all treatment minus that of
hospice care)/estimated QALE with all treatments minus
that of hospice care. We adopted the criterion suggested by
WHO-CHOICE (World Health Organization-CHOosing In-
terventions that are Cost Effective), and applied one to
three times the gross domestic product (GDP) per capita as
the threshold for cost effectiveness.24 Taiwan’s GDP per
capita in 2010 was US$19,278.25
Similarly, patients with ESRD were also waived from
copayment under the NHI and usually passed away within 3
months after discontinuing dialysis. We thus assumed 3
months of life expectancy for ESRD patients, and the utility
value was assumed to be 0.4 under palliative or hospice
care. Again, because PMV patients require a ventilator
every day for at least 6 hours to remain alive, and they
continued using a ventilator for > 21 days and were waived
from copayment, we assumed immediate mortality for PMV
patients without mechanical ventilation.10
Uncertainties and validation of the extrapolation
method for different illnesses
In estimating uncertainty and validation, an ex post
approach was used instead of the conventional ex ante.
Survival data were based on real follow-up for at least10e13 years. The healthcare expenditures were directly
retrieved from the reimbursement data files of the NHI
system. The standard errors of the mean were calculated
by the bootstrap method for 100 repeated samples in these
parameters, including QALE and lifetime cost. Since sur-
vival is the most important determinant of lifetime cost, we
validated our extrapolation method in the following
manner: Survival of subcohorts of patients with different
illnesses between 1998 and 2003 was analyzed by the KeM
method, and then these results were extrapolated to the
end of 2010 by our semiparametric method, which were
compared with the KeM estimates of the actual 13 years of
follow-ups (namely, from 1998 to 2010). Assuming that the
KeM estimates were the gold standard, we calculated the
relative biases for subcohorts with different illnesses and
cancer. The relative bias is defined as follows:
relative bias Z (estimate from extrapolation  KeM esti-
mate)/KeM estimate. (1)
Sensitivity analysis for cost-effectiveness
As the life span of patients under hospice care might be too
short, we assumed an average life expectancy of 2 years and
an average QoL value of 0.5 after the diagnosis of each type of
cancer in the “no treatment scenario” to conduct a sensitivity
analysis for cost effectiveness of cancer care. To be fair about
the healthcare expenditures of cancer care for such a
Table 2 CIR20e79 (%) of major cancers stratified by gender
and calendar years.
Site of
cancer
Gender 1998e2002 2003e2007 2008e2010
Lung Male 5.18 5.72 6.05
Female 2.54 2.77 3.15
Esophagus Male 1.06 1.34 1.55
Female 0.11 0.11 0.12
Liver Male 5.99 6.67 6.80
Female 2.66 2.95 3.12
Stomach Male 2.60 2.37 2.08
Female 1.42 1.22 1.13
Colorectum Male 4.68 5.53 6.30
Female 3.82 4.07 4.36
Oral Male 2.05 2.63 2.99
Female 0.30 0.33 0.38
Nasopharynx Male 1.02 0.92 0.88
Female 0.42 0.32 0.29
Breast Female 4.68 5.44 6.52
Cervix Female 3.32 1.94 1.37
CIR20e79Z cumulative incidence rate from age 20 years to 79
years.
614 M.-C. Hung et al.scenario, we also assumed that the lifetime costs of cancer
patients would be the same as those of the hospice care.
Estimation of cumulative incidence rates of major
cancers
We used the Catastrophic Illnesses Registry for the period
1998e2010 to calculate the incidence rates of major can-
cers. The cumulative incidence rate (CIR) from age 20 years
to 79 years was calculated to estimate the lifetime risk of a
specific illness, as follows:
CIR Z 1  exp[Si(IRi)$(Dti)] (2)
where IRi represents the age-specific incidence rate and Dti
indicates the range of each age stratum.
Results
We excluded about 1% of invited patients who were totally
unable to communicate with research assistants for the QoL
interview, plus 9% who refused to be interviewed. Of the
nine different cancers studied, even though patients with
cervical cancer were not the youngest at diagnosis, their
QALE was the longest, i.e., 25.9 QALY (Table 1 and
Figure 2). Patients under hospice care were usually older
and were responsible for less healthcare expenditures than
those under regular treatment. Nasopharyngeal cancer
represented the highest lifetime healthcare expenditure in
males and females, with estimates of US$29,809 and
US$30,225, respectively. All of the nine different cancers
were reimbursed for < 1 GDP per capita per QALY. Lung,
esophagus, and liver cancers showed the highest cost per
QALY, with 0.42e0.49 GDP, 0.25e0.44 GDP, and 0.24e0.25
GDP per capita per QALY, respectively. The estimated
quasi-ICER for these cancers ranged from 0.36 to 0.42 GDP,
from 0.19 to 0.39 GDP, and from 0.22 to 0.23 GDP per capita
per QALY, respectively. There is a general trend of shorter
QALE being associated with higher cost per QALY. ESRD
caused the highest life-time healthcare expenditure at
US$129,658e138,487. PMV had the highest cost per QALY
followed by ESRD, which were estimated at 2.17e2.79 GDP
and 1.18e1.25 GDP per capita per QALY, respectively (Table
1 and Figure 2).
The results obtained to validate our semiparametric
method show that the relative biases of extrapolation from
the end of the 6th year to that of the 13th year were all
below 11% (Table A1), which would be even smaller after
our actual follow-up for 13 years. In addition, the sensi-
tivity analysis of cost effectiveness for cancer care showed
a consistent result of less than 1 GDP per capita, or
0.04e0.86 GDP per capita, for care of cancers of different
organ systems in comparison with no treatment. We found
that the top three quasi-ICERs were US$16,631 and
US$10,520 for male and female lung cancer, US$12,738 and
US$4,801 for male and female esophageal cancer, and
US$5440 and US$5555 for male and female liver cancer,
respectively (Table A2). The lifetime risk (CIR20e79) of
major cancers has continually increased over the past
decade, except that for stomach, nasopharyngeal, and
cervical cancers (Table 2).Discussion
We found that the cost per QALY for treating cancer at
different major organ sites is < 1 GDP per capita in Taiwan,
from the perspective of the NHI. The following arguments
support this inference: First, to ensure the quality of di-
agnoses, we included only cancer patients verified with
pathology (except liver cancer26) and registered with the
Taiwan Cancer Registry; patients who were hospitalized
with PMV and those with ESRD were all registered in the
Catastrophic Illnesses Registry, and thus their diagnoses had
been validated by at least two specialists to ensure no
abuse with regard to waiving copayments. Second, we
ensured that all the extrapolations were made through the
verification of the existence of a “constant excess hazard,”
which can be obtained by showing a straight line after
taking the logit transform of the survival ratio between the
index and age- and gender-matched referents.14e16,18
Moreover, we further validated these estimations by
extrapolating the survival for the first 6 years up to 13
years, and showed that there was generally < 11% error in
comparison with the actual survival based on the KeM
method (Table A1). As the survival functions of all patients
in this study (except those under PMV) were estimated
based on > 13 years of follow-up, at which the majority of
cancer patients would be deceased, the estimation of life
expectancy would be more accurate. Third, because all
patients registered in the Catastrophic Illnesses Registry of
the NHI are waived from any copayments, all related costs
for treating these illnesses would be very comprehensive
and comparable. Fourth, we assigned 22,344 cancer pa-
tients under hospice care to a comparison group for quasi-
ICER analysis, and the results appeared similar (Table 1).
We also used cancer patients without treatment as another
comparison group to conduct a sensitivity analysis of cost
effectiveness of care for cancers of different organ sys-
tems, which showed 0.04e0.86 GDP per capita (Table A2).
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ita. Therefore, we tentatively concluded that the cost per
QALY of all cancer management is less than that for PMV
and ESRD. As all these values of cancer management were
< 1 GDP of Taiwan per capita per QALY, they are relatively
cost effective based on the criteria proposed by WHO.24
Based on qualitative analysis, we attribute the apparently
low cancer care cost to the following reasons: most of the
related hospitals are nonprofit organizations in Taiwan; the
NHI has adopted and encouraged hospice care for terminal
cancer patients since 1996; the country currently spends only
w6.9% ofGDPon total healthcare expenditure,which is lower
than the figures for most countries of the Organization for
Economic Cooperation and Development.27 Nonetheless,
continued efforts to develop more cost-effective clinical
guidelines for cancer care3,4 should be encouraged, in order
to ensure the sustainability of the NHI system.
Financial burdens of cancer care also depend on the inci-
dence rates. For direct comparison, we quantified the life-
time risk of major cancers by calculating the CIR20e79, which
shows a consistent rising trend over the past decade (Table 2),
except for cervical, nasopharyngeal, and stomach cancers.
Therefore, total healthcare expenditures would still increase
in the future, even ifwewere able to hold down cost per QALY
by sticking to more cost-effective management guidelines.
This issue requires special attention, especially with regard to
prevention, if we hope to achieve a system of sustainable and
affordable cancer care.3,28 In addition to reducing occupa-
tional and environmental risks, stakeholders and care pro-
vidersmay consider tackling the issue from thewhole cycle of
care.29 Cancer screening for early detection and prompt
treatment may be one of the viable choices, as has been
demonstrated in case of cervical cancer.30,31
Limitations
Our study has the following limitations. First, because the
reimbursement data we used were only up to 2009, we
were unable to include many new medications and treat-
ments that might be more expensive than those used during
this period. For example, some molecular target therapies
have been covered by the NHI in Taiwan since 2011, such as
bevacizumab and cetuximab for colorectal cancer, and
sorafenib for liver cancer. The application criteria for some
of these therapies were broadened after 2011, such as
those for erlotinib and gefitinib for lung cancer, and tras-
tuzumab for breast cancer.32 Therefore, the lifetime health
expenditure or cost per QALY for colorectal, liver, and
several other cancers treated with these new medications
could be higher after 2009. Careful monitoring of such ex-
penditures is thus necessary in the future to ensure the
efficiency and equity of the NHI system. Second, during
extrapolation, we assumed that the QoL of the patients
remained the same as that measured at the end of the
follow-up period. However, this assumption could result in
an overestimation of the QALE, because the actual QoL
might gradually decline with age and increasing comorbid-
ity.33,34 In general, such an overestimation would be higher
in elderly patients than that in younger ones, which must be
considered if we are comparing different diseases with
various ages at diagnosis. However, because we followed
these patients for 13 years and applied the same estimationmethod for all diseases in this study, the bias might not be
too large. Third, as most of the interviewed patients were
recruited from clinics, their general conditions were prob-
ably better than those confined at home or in institutions.
Our results might thus have overestimated the QoL and
QALE. However, since we applied the same strategy for
recruitment of patients with cancers of different organ
systems, such an overestimation might not have produced
too much bias among them. Finally, this study is conducted
from the viewpoint of a single payer, namely, the NHI. As
the financial difficulty has become heavier, bundle pay-
ment (e.g., Diagnosis Related Group) has been adopted
step by step to slow down the growth of financial demand,
which might result in a potential bias on the estimation of
reimbursement costs. However, since cancer treatment is
not yet included in the Diagnosis-Related Group payment
system in Taiwan, and bundle payment would usually
decrease or underestimate the costs, such a system will not
change the conclusion of this study. Instead, future studies
must take such a potential impact into consideration.
Conclusion
In conclusion, treatments of major cancers in Taiwan
appeared affordable up to 2009 if we compared them with
those of patients under PMV or with ESRD, or applied a cutoff
point of 1 GDP per capita per QALY. However, since the
incidence rates of major cancers have continually increased
over the past decade, except those for stomach, nasopha-
ryngeal, and cervical cancers, proactive prevention remains
the key approach to make the NHI more sustainable. We
recommend that future studies consider evaluating the cost
effectiveness of different prevention programs for direct
comparison across prevention,28 diagnosis and treatment,
rehabilitation, and alternative medicine.35
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616 M.-C. Hung et al.AppendixFigure A2 Lifetime healthcare expenditures for males with
colorectal cancer. The monthly survival probability
(NZ 43,731) was multiplied by the monthly expenses and
summed up for a lifetime (shaded areas), which amounts to
US$24,677  1741 (3% discount).
Figure A1 QALE for males with colorectal cancer. A total of
43,731 patients were followed for 13 years, and their data
were extrapolated throughout lifetime to obtain the survival
function, which was adjusted by the utility values measured
with the EQ-5D (NZ 817). The total area under the quality-
adjusted survival curve (shaded areas) was then summed up
as the QALE, which was 9.9  0.1 QALYs. EQ-5DZ EuroQoL
five-dimension; QALEZ quality-adjusted life expectancy;
QALYZ quality-adjusted life year.Table A1 Estimates of mean survival years in 13 years of follow-up using the semiparametric method of extrapolation based
on the first 6 years of follow-up data with a high censored rate, compared with the KeM estimates of 13 years of follow-up for
patients with major cancers and ESRD.
Illness Gender Cohort
size
Age at
diagnosis
(SD)
Censored
rate (%)
13 y survival based
on KeM estimate
(SE)
(mo)
Extrapolation
based on
the first 6 y
of followeup
(SE) (mo)
Relative
bias (%)a
Cancer site
Lung Male 25,118 67.8 (11.3) 24.3 22.9 (0.3) 23.3 (0.5) 1.8
Female 11,355 64.5 (13.0) 31.0 29.0 (0.5) 29.2 (0.9) 0.9
Esophagus Male 6099 60.6 (12.6) 28.5 25.9 (0.5) 28.8 (1.0) 10.8
Female 534 68.1 (13.3) 37.5 42.3 (2.6) 41.3 (4.4) e2.4
Liver Male 15,719 58.7 (13.4) 43.9 44.1 (0.5) 44.8 (1.8) 1.8
Female 5730 62.2 (13.1) 46.1 46.2 (0.7) 43.1 (2.5) e6.6
Stomach Male 13,719 67.2 (13.1) 44.7 52.0 (0.6) 51.2 (1.3) e1.5
Female 7042 63.5 (15.2) 49.6 61.5 (0.8) 60.8 (1.9) e1.1
Colorectum Male 22,744 65.0 (13.2) 64.7 77.6 (0.4) 76.6 (2.1) e1.3
Female 17,095 64.1 (14.2) 67.1 84.4 (0.4) 80.3 (2.8) e4.9
Oral Male 12,998 51.7 (12.2) 64.3 78.7 (0.5) 75.6 (1.7) e3.9
Female 1467 59.0 (15.8) 71.2 91.3 (1.6) 92.6 (4.6) 1.4
Nasopharynx Male 6065 49.5 (13.2) 71.9 88.9 (0.8) 88.9 (2.2) 0.0
Female 2161 48.8 (13.8) 77.9 103.4 (1.4) 96.2 (3.9) e7.0
Breast Female 29,925 50.5 (12.2) 88.5 123.6 (0.3) 120.0 (2.2) e2.9
Cervix Female 36,749 51.6 (14.3) 90.9 133.4 (0.3) 133.9 (0.8) 0.4
ESRD Male 31,459 58.6 (15.1) 63.3 76.6 (0.3) 75.9 (0.7) e0.9
ESRDZ end-stage renal disease; KeMZ KaplaneMeier; SDZ standard deviation; SEZ standard error of mean.
a Relative biasZ (estimate from extrapolation e KeM estimate)/KeM estimate.
Table A2 Sensitivity analysis of cost effectiveness for
care of cancers of different organ systems, stratified by sex.
Cancer site Sex Patients without
treatment
Quasi-ICERa
QALE
(survivalZ 2 y;
utilityZ 0.5)
Lifetime
costb
(3%
discount)
Lung Male 1.0 3139 16,631
Female 1.0 3619 10,520
Esophagus Male 1.0 3028 12,738
Female 1.0 4465 4801
Liver Male 1.0 2786 5440
Female 1.0 2339 5555
Stomach Male 1.0 2219 4696
Female 1.0 2608 3139
Colorectum Male 1.0 3108 3446
Female 1.0 3450 2828
Oral Male 1.0 4353 3305
Female 1.0 3754 2458
Nasopharynx Male 1.0 5783 3251
Female 1.0 5398 2398
Breast Female 1.0 5007 1813
Cervix Female 1.0 4809 855
ICERZ incremental cost-effectiveness ratio; QALEZ quality-
adjusted life expectancy, the unit is year.
a Quasi-ICER, calculated based on the difference between
patients with and without treatment, and both QALE and life-
time cost were applied (with 3% discount).
b Estimation of lifetime cost (in US dollars) assumed that the
monthly cost of “no treatment scenario” is the same as that of
hospice care.
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